Authors
Latest:
Case report details spontaneous bladder rupture caused by herpes zoster–associated urinary retentionAlthough cases of acute urinary retention and defecation caused by herpes zoster in the sacral area have been reported, no clinical cases about spontaneous bladder rupture have been previously published, according to the authors.
Latest:
Molecular diagnostic practice in prostate and bladder cancers"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.
Latest:
Strategies to mitigate impact of intravenous ICM shortage"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.
Latest:
Future Perspectives in the Treatment of Patients With Urinary StonesDrs Bechis and Semins discuss future developments in urinary stone management, emphasizing the potential for improved vacuum aspiration devices, combined intravenous and PCNL surgeries, and the hope for medications to dissolve stones.
Latest:
Money Matters: Informing your perspective on the bear marketNo matter what your age or risk tolerance, investing is a lot easier and likely more successful if your perspective is informed by market history.
Latest:
Expert explains challenges of telehealthAlthough much of the discourse around telehealth rightfully focuses on its benefits, the potential drawbacks and limitations are often glossed over, particularly around provider burden.
Latest:
EP. 3B: Mitomycin-containing Reverse Thermal Gel Technology as a Kidney-sparing Treatment Option for Patients with LG UTUCIn this companion article, Sam S. Chang, MD, MBA, offers his expert perspective on the use of mitomycin gel as a kidney-sparing approach to the management of low-grade upper tract urothelial carcinoma.
Latest:
Ensuring operational continuity is critical with healthcare data breachesWith healthcare data breaches approaching a boiling point, care providers need to adopt an approach that prioritizes operational continuity.
Latest:
Frontline Therapy for Non-Metastatic Muscle-Invasive Bladder CancerFrontline treatment approaches recommended by urologists and medical oncologists for patients with non-metastatic muscle-invasive bladder cancer.
Latest:
Managing aging and frailty in the urologic cancer populationIncreasing numbers of older patients with cancer necessitates adoption of an age-friendly approach to cancer care.
Latest:
Lenvatinib/pembrolizumab benefit in ccRCC sustained across subgroupsA post hoc analysis from the phase 3 CLEAR trial showed that frontline lenvatinib plus pembrolizumab elicited improved tumor response vs sunitinib across subgroups of patients with clear cell renal cell carcinoma.
Latest:
Enzalutamide sustains survival benefit in mHSPC with over 5 years’ follow-up“ENZAMET adds to the body of knowledge from several other pivotal trials and now informs best practices for mHSPC,” said Ian D. Davis, MBBS, PhD, FRACP, FAChPM.
Latest:
Update on advanced imaging in prostate cancerAdvances allow for more accurate detection of metastatic disease.
Latest:
Impact of Rectal Spacers on Sexual Quality-of-Life After Radiotherapy in Patients With Prostate CancerAnalysis of SpaceOAR trial and pooled data found reduced penile bulb radiation dose correlated with better preservation of sexual function over long-term follow-up, suggesting rectal spacers help maintain erectile function in some men with prostate cancer undergoing radiation therapy.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
How to implement an ERAS pathway in your urology practiceProgram encompasses patient counseling, anesthetic planning, and early mobilization.
Latest:
What is H.R. 2472?The bill, H.R. 2474, would tie the Medicare physician fee schedule to the Medicare Economic Index (MEI), something the AACU and the AMA have long supported
Latest:
Expert Forum: Fertility after exogenous testosterone replacementTreatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.
Latest:
Distinguishing between malignant and benign renal masses"Augmented biopsy-based and noninvasive options are available to reduce benign resection rates of renal tumors with the consideration of PEER and 99mTc-sestamibi SPECT/CT," writes Hiten D. Patel, MD, MPH.
Latest:
Optimization of Genetic Testing for mCRPCJason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.
Latest:
Diagnostic stewardship for urinary tract infection: A snapshot of the expert guidanceUrinary tract infections (UTIs) are among the most common human infections. But the urine culture, the cornerstone for laboratory diagnosis of UTI, is imperfect.
Latest:
How to implement an ERAS pathway in your urology practiceProgram encompasses patient counseling, anesthetic planning, and early mobilization.
Latest:
The American Board of Urology: Considerations for the urologist in career transitions"The ABU continues to reevaluate all policies related to diplomates. As medical practice continues to evolve in United States, and these changes affect the practitioners of medicine, likely further changes will be necessary in board certification procedures," writes Roger Dmochowski, MD, MA (Conflict Management and Resolution), MMHC, FACS.
Latest:
UCI receives renewal as Orange County’s only federally designated comprehensive cancer centerThe National Cancer Institute has again recognized the UCI Chao Family Comprehensive Cancer Center as one of the nation’s top cancer centers, renewing its “comprehensive” designation
Latest:
GNRH agonists vs antagonists in prostate cancer: How to chooseMany factors play into decision-making process when weighing agents.
Latest:
Legislative efforts to eliminate barriers to prostate cancer screening ramp up"Our success depends on your assertive action and membership in organizations serving our specialty—the AACU in particular—as well as your state medical association," writes William C. Reha, MD, MBA.
Latest:
EU approval sought for erdafitinib for FGFR3+ urothelial carcinomaThe EU application for erdafitinib in urothelial carcinoma is supported by data from cohort 1 of the phase 3 THOR trial.
